GnRH antagonist monotherapy versus a GnRH agonist plus bicalutamide for advanced hormone-sensitive prostate cancer; KYUCOG-1401.

Akira Yokomizo Masaki ShiotaFutoshi MorokumaMasatoshi EtoHideyasu MatsuyamaHiroaki MatsumotoToshiyuki KamotoNaoki TeradaKazuya KawaharaHideki EnokidaShuichi TataranoNaohiro FujimotoKatsuyoshi HigasijimaHideki SakaiTomoaki HakariyaTsukasa IgawaShigetaka SuekaneTomomi KambaYutaka SugiyamaJunji KishimotoSeiji Naito

Published in: International journal of urology : official journal of the Japanese Urological Association (2023)

The present results support the potential of CAB using a GnRH agonist and bicalutamide as a more effective treatment for advanced HSPC than GnRH antagonist monotherapy.

Keyphrases

prostate cancer
combination therapy
open label
radical prostatectomy
clinical trial
randomized controlled trial
study protocol